Home > Oncology > BCC 2019 > St. Gallen Consensus > Endocrine therapy in premenopausal patients

Endocrine therapy in premenopausal patients

Conference
BCC 2019
Trial
SOFT, TEXT
The first question the panel had to answer on this topic was the ideal cut-off – in terms of percentage of ER-positive tumour cells – to prescribe endocrine therapy. There was no clear consensus on this topic: 30% of the panellists voted for >1%, 4% voted for >5%, 39% voted for >10%, while 25% took the view that there is no clear answer. Recently, updates were presented of the SOFT and TEXT trial [1] showing that among premenopausal women with breast cancer, the addition of ovarian suppression to tamoxifen resulted in significantly higher 8-year rates of both disease-free and overall survival than tamoxifen alone. The use of exemestane plus ovarian suppression resulted in even higher rates of freedom from recurrence. Based on these results, a majority of the panellists (68%) took the view that premenopausal patients with an ER-positive tumour who are getting adjuvant chemotherapy are candidate for ovarian function suppressive (OFS) therapy. Also in line with the SOFT and...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on